Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort

Naylor, Kyla L.; Kim, S. Joseph; McArthur, Eric; Garg, Amit X.; McCallum, Megan K.; Knoll, Gregory A.

doi:10.1053/j.ajkd.2018.12.011

Cited by 95 publications

(73 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More commonly, in patients inadequately responsive to the SOC, progressive organ damage over time leads to partial and eventually complete loss of renal function. While some renal functions can be replaced by dialysis, a recent analysis demonstrates that survival of patients on dialysis can be lower than for several types of cancer …”

Section: Example 1: General Sle Vs Lupus Nephritismentioning

confidence: 99%

“…While some renal functions can be replaced by dialysis, a recent analysis demonstrates that survival of patients on dialysis can be lower than for several types of cancer. 18 The current SOC for LN is described in Table 2. In spite of available therapeutic options, response to therapy is slow and incomplete, with only 25-50% of patients achieving complete remission by 2 years and the majority experiencing a relapse within 5 years, despite continued immunosuppressive therapy.…”

Section: Example 1: General Sle Vs Lupus Nephritis 17mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

Liu

Fields²,

Prescott

et al. 2019

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

A significant regulatory gap exists to facilitate global development of therapeutics for nononcology severely debilitating or life‐threatening diseases or conditions (SDLTs). In a 2017 publication, a streamlined approach to the development of treatments for SDLTs was proposed to facilitate earlier and continued patient access to new, potentially beneficial therapeutics.1 However, a major hindrance to broad adoption of this streamlined approach has been the lack of universally accepted, objective criteria to define SDLTs. This article serves to extend the 2017 publication by further addressing the challenge of defining SDLT scope in order to stimulate broader discussion and facilitate development of regional and ultimately international guidelines on the development of therapeutics for SDLTs. Using case examples, we describe key attributes of SDLTs and provide criteria for consideration of an SDLT scope definition.

show abstract

Section: Example 1: General Sle Vs Lupus Nephritismentioning

confidence: 99%

Section: Example 1: General Sle Vs Lupus Nephritis 17mentioning

confidence: 99%

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

Liu

Fields²,

Prescott

et al. 2019

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Смертність від усіх причин даної когорти хворих залишається стабільно високою -> 20% щорічно та в 10 разів перевищує цей показник в загальній популяції [1]. 5-річна виживаність становить лише близько 40% незалежно від режиму діалізу, та є гіршою, ніж у багатьох видів раку [1][2][3]. Серцево-судинні ускладнення є провідною причиною захворюваності та смертності у діалізних хворих.…”

unclassified

Cardiovascular complications in hemodialysis patients: current approaches to prolong and improve quality of patients’ life

Prusskiy¹

2019

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

Cardiovascular complications are a leading cause of morbidity and mortality in dialysis patients. Cardiovascular mortality is more than 40% of the total mortality in this cohort of patients. Recently, there has been an increase in publications on the role of uremic toxins, including “middle molecules”, in the development and progression of cardiovascular complications in dialysis patients. Conventional low-flux (LF) hemodialysis well removes small molecular weight uremic toxins not bound with protein. Evidence for the role of "middle molecules" in the development of many complications, including cardiovascular complications, has contributed to the emergence and development of such dialysis therapy methods as high-flux (HF) hemodialysis, hemofiltration (HF) and hemodiafiltration (HDF). Further evolution of membrane technology has led to the development of protein-leaking membranes or super-flux or high cutoff (HCO) membranes. These membranes are capable of removing molecules in excess of the molecular weight of albumin. The use of these membranes is limited because of the risk of hypoalbuminemia. Today, the closest approximation to the natural glomerular membrane is the so-called Middle Cut-Off (MCO) membrane. The use of MSO membranes is implemented in a new method of dialysis therapy - expanded hemodialysis (HDx). The method is defined as a treatment where diffusion and convection are conveniently combined inside a hollow-fibre dialyser equipped with an MCO membrane. A standard hemodialysis machine is used for the HDx. Increased removal of large medium molecules in HDx may lead to an improvement of clinical outcomes, including a decrease of the cardiovascular events incidence, an all-cause and cardiovascular mortality reduction in dialysis patients.

show abstract

“…S. Ali Husain, MD, MPH, assistant professor of medicine at Columbia University Medical Center in New York City, believes the new research shows that many discarded kidneys are actually transplantable and that the paper “might even further underestimate how many kidneys could be utilized.” Evidence suggests that dialysis is associated with a high level of morbidity and mortality and that patients fare better with a transplant—any transplant 2 . “We know for sure that dialysis is way worse than getting a transplant,” says Dr. Husain.…”

mentioning

confidence: 99%

Discarding Kidneys—Can We Do Better?

Pullen¹

2019

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort

Cited by 95 publications

References 27 publications

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

Cardiovascular complications in hemodialysis patients: current approaches to prolong and improve quality of patients’ life

Discarding Kidneys—Can We Do Better?

Contact Info

Product

Resources

About